Filing Flows › Northwest Biotherapeutics (NWBO) › Q1 2025
Northwest Biotherapeutics (NWBO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Northwest Biotherapeutics (NWBO) reported revenue of $375K for the first quarter 2025 (Q1 2025), +32% from a year earlier and +62% from the quarter before.
Northwest Biotherapeutics, Q1 2025: revenue $375K (+32% year over year), net loss $19.3M, operating cash flow −$9.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $375K | +62% | +32% |
| Operating profit | −$17.3M | — | — |
| Net earnings | −$19.3M | — | — |
| Operating cash flow | −$9.4M | — | — |
What changed
Revenue was $375K in Q1 2025, up 32% year over year and up 62% from the previous quarter.
Operating costs exceeded revenue by $17.3M, an operating margin of -4616.3%. Total costs grew 10% against revenue growth of 32%. The fastest-growing cost line was General & admin (+15%). The quarter ended with a net loss of $19.3M, narrower than the previous quarter's $28.2M loss.
Operating cash flow was −$9.4M. Non-cash charges added back $400K of depreciation and $385K of share-based compensation. Working capital and other items added $9.1M. Capital expenditures of $93K exceeded it, leaving free cash flow of −$9.5M.
Questions
What was Northwest Biotherapeutics' revenue in the first quarter 2025?
Northwest Biotherapeutics (NWBO) reported revenue of $375K for the first quarter 2025 (Q1 2025), +32% from a year earlier and +62% from the quarter before.